FDA issues an Early Communication About an Ongoing Safety Review of Tumor Necrosis Factor (TNF) Blockers (marketed as Re
This is a discussion on FDA issues an Early Communication About an Ongoing Safety Review of Tumor Necrosis Factor (TNF) Blockers (marketed as Re within the FDA News forum, part of the Industry News and Updates category; FDA issues an Early Communication About an Ongoing Safety Review of Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, ...
|
|||||||
| Register | Help | Members List | Mark Forums Read |
06-07-2008, 07:30 PM
|
|||
|
|||
FDA issues an Early Communication About an Ongoing Safety Review of Tumor Necrosis Factor (TNF) Blockers (marketed as Re
FDA issues an Early Communication About an Ongoing Safety Review of Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, and Cimzia)
More... 
|
 |
«
Previous Thread
|
Next Thread
»
| Thread Tools | |
| Display Modes | |
Linear Mode
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| FDA approves new Medication Guide and Label for Varenicline (marketed as Chantix) | industry_news | FDA News | 0 | 05-19-2008 03:47 PM |
| CDER issues "Review of Therapeutic Equivalence Generic Bupropion XL 300 mg and Wellbutrin XL 300 mg" | industry_news | FDA News | 0 | 04-17-2008 06:51 PM |
| FDA issues an Early Communication about an Ongoing Safety Review for Botox | industry_news | FDA News | 0 | 02-26-2008 03:30 PM |
| FDA Issues Early Communication about an Ongoing Review of Vytorin | industry_news | FDA News | 0 | 02-26-2008 03:30 PM |
© 2008 DrugManagementForum™ powered by |
 |